GO
| HSI1 | 25,116.53 | -177.50 | 243.63B |
| HSCEI1 | 8,456.92 | -47.89 | 82.60B |
| Back Zoom + Zoom - Block Traded | |
|
2026-04-02 10:30:00 BOCI issued a research report noting that 3SBio (01530.HK)'s results last year missed expectations. Revenue increased 94.3% YoY to RMB17.7 billion, mainly driven by RMB9.4 billion in licensing income contributed by the licensing agreement with Pfizer (PFE.US), partially offset by weak drug sales. Excluding licensing income, core profit declined due to a drop in gross margin and an increase in operating expenses. On the other hand, SSGJ-707, positioned by Pfizer as a next-generation cornerstone immuno-oncology product, is expected to generate milestone income from Pfizer as the latter has initiated and plans to launch relevant clinical trials in 2026. The broker raised its TP for 3SBio to HKD38.3 from HKD38.2 and maintained a Buy rating. (ca/j)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |